Comparative Pharmacology
Head-to-head clinical analysis: FOTIVDA versus FRUZAQLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOTIVDA versus FRUZAQLA.
FOTIVDA vs FRUZAQLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), thereby inhibiting angiogenesis and tumor growth.
Fruzaqla (fruquintinib) is a selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR-1, -2, -3), blocking VEGF-mediated signaling and thereby inhibiting tumor angiogenesis and tumor growth.
39 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Adult: 5 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 111 hours (range 79–184 hours) in patients with advanced renal cell carcinoma. This long half-life supports once-daily dosing and steady-state is reached within 2–3 weeks.
Terminal elimination half-life is approximately 20–30 hours, supporting once-daily dosing.
Primarily hepatobiliary (fecal) elimination: 87% in feces (15% as unchanged drug, 72% as metabolites). Renal excretion accounts for approximately 6% of the dose (mostly metabolites).
Primarily hepatic metabolism (CYP3A4) followed by fecal excretion (77% of dose as metabolites, 20% as unchanged drug) and renal excretion (<1% unchanged).
Category C
Category C
VEGFR inhibitor (Antineoplastic)
VEGFR inhibitor (Antineoplastic)